8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 8 of 8 clinical reviews.
Analysis of FDA Adverse Event Reporting System (FAERS) safety signals for Dayvigo (lemborexant), including somnolence, sleep paralysis, complex sleep behaviors, and suicidal ideation reports since approval.
A detailed review of Dayvigo (lemborexant) regulatory approvals worldwide, including FDA clearance, EMA authorization, and post-market safety surveillance data from SUNRISE clinical trials.
A detailed comparison of how the FDA and EMA evaluated and regulated Dayvigo (lemborexant), including approval timelines, label differences, scheduling, and post-market safety requirements.
A complete guide to Dayvigo (lemborexant) FDA approval status, compounding legal status, label requirements, and post-market safety data. Reviewed by board-certified physicians.
A complete record of Dayvigo (lemborexant) FDA approval history, label changes, clinical trial data from SUNRISE-1 and SUNRISE-2, scheduling, and post-market safety updates.
A complete clinical reference covering every Dayvigo (lemborexant) FDA label change from initial approval in December 2019 through 2026, including dosing guidance, contraindications, post-market safety signals, and prescribing implications.
A clinician-reviewed guide to lemborexant (Dayvigo) covering FDA approval history, patent disputes, label warnings, and post-market safety surveillance data.
A clinical review of Dayvigo (lemborexant) regulatory history, current FDA label, post-market safety data, and Eisai's pipeline for next-generation orexin receptor antagonists.